Patients who have completed l-fmau-301, l-fmau-302 or l-fmau-303
Item
1. the patients who have completed l-fmau-301, l-fmau-302 or l-fmau-303.
boolean
C2348568 (UMLS CUI [1])
patients who have showed complete response after completion of l-fmau-301 or l-fmau-302 and treated with the clevudine
Item
2. patients who have showed complete response (alt normalization and hbv dna <4,700 copies/ml in l-fmau-301 or l-fmau-302, in addition, hbeag seroconverted to anti-hbe at the last two visits in l-fmau-301) after completion of l-fmau-301 or l-fmau-302 and treated with the clevudine.
boolean
C0201836 (UMLS CUI [1])
C3641250 (UMLS CUI [2])
C1167869 (UMLS CUI [3,1])
C0019167 (UMLS CUI [3,2])
Patients who have showed complete response after completion of l-fmau-303
Item
3. patients who have showed complete response (alt normalization and hbv dna <4,700 copies/ml, in addition hbeag seroconverted to anti-hbe at the last two visits who showed hbeag positiv at baseline) after completion of l-fmau-303
boolean
C0201836 (UMLS CUI [1])
C3641250 (UMLS CUI [2])
C1167869 (UMLS CUI [3,1])
C0019167 (UMLS CUI [3,2])
Informed Consent
Item
4. patients who were able to give written informed consent prior to study start and to comply with the study requirements.
boolean
C0021430 (UMLS CUI [1])
Bilirubin levels, prothrombin time, serum albumin
Item
5. patients with bilirubin levels less than 2.0 mg/dl, prothrombin time of less than 1.7 (inr), and a serum albumin level of at least 3.5 g/dl at the last visit in l-fmau-301, l-fmau-302 or l-fmau-303.
boolean
C0344395 (UMLS CUI [1])
C0033707 (UMLS CUI [2])
C0523465 (UMLS CUI [3])
Patients who have showed complete response but previously treated with placebo
Item
1. patients who have showed complete response but previously treated with placebo in the l-fmau-301, l-fmau-302.
boolean
C0521982 (UMLS CUI [1,1])
C0032042 (UMLS CUI [1,2])
Antiviral, immunomodulatory or corticosteroid therapy
Item
2. patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy.
boolean
C0280274 (UMLS CUI [1])
C1963758 (UMLS CUI [2])
C0149783 (UMLS CUI [3])
interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for hbv infection.
Item
3. patients previously treated with interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for hbv infection.
boolean
C0021747 (UMLS CUI [1])
C0209738 (UMLS CUI [2])
C0286536 (UMLS CUI [3])
C0209227 (UMLS CUI [4])
C0050175 (UMLS CUI [5])
C1579410 (UMLS CUI [6,1])
C0019163 (UMLS CUI [6,2])
Ascites, variceal hemorrhage or hepatic encephalopathy
Item
4. patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy.
boolean
C0003962 (UMLS CUI [1])
C0333106 (UMLS CUI [2])
C0019151 (UMLS CUI [3])
hcv, hdv or hiv infection
Item
5. patients co-infected with hcv, hdv or hiv.
boolean
C0019196 (UMLS CUI [1])
C0011226 (UMLS CUI [2])
C0019693 (UMLS CUI [3])
liver mass (hemangioma, nodule), biliary disease
Item
6. patients with a liver mass (hemangioma, nodule), biliary diseases except asymptomatic gb stone during the l-fmau-301, l-fmau-302 or l-fmau-303.
boolean
C0238246 (UMLS CUI [1])
C0745761 (UMLS CUI [2])
C0016977 (UMLS CUI [3])
Pregnant or breast feeding
Item
7. patients who were pregnant or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Significant gastrointestinal, renal, hepatic (decompensated), biliary diseases, bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease
Item
8. patients with a significant gastrointestinal, renal, hepatic (decompensated), biliary diseases except asymptomatic gb stone, bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease. the patients with a benign tumor were excluded if judged by an investigator that the continuation of study would be interfered by benign tumor.
boolean
C0017178 (UMLS CUI [1])
C0022658 (UMLS CUI [2])
C0023895 (UMLS CUI [3,1])
C0205434 (UMLS CUI [3,2])
C0016977 (UMLS CUI [4])
C1096000 (UMLS CUI [5])
C0027765 (UMLS CUI [6])
C0007222 (UMLS CUI [7])
C0027651 (UMLS CUI [8])
C0020517 (UMLS CUI [9])
Patients not suitable to the study
Item
9. patients who were not suitable to the study if judged by an investigator.
boolean
C1321605 (UMLS CUI [1])